Baughman R P, Winget D B, Bowen E H, Lower E E
Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267-0564, USA.
Sarcoidosis Vasc Diffuse Lung Dis. 1997 Sep;14(2):154-8.
Although sarcoidosis is a multisystem disease, mortality from sarcoidosis is usually due to respiratory failure. In order to identify those patients at risk of death from respiratory failure from sarcoidosis, we analyzed a seven-year experience of patients seen at the University of Cincinnati Interstitial Lung Disease clinic.
A total of 479 patients were seen during that time. Of these, 22 (4.6%) died. Thirteen patients died from respiratory failure, three died from cardiac disease, and two each from neurologic or hepatic disease. Two patients died from unrelated disease. Analysis of the patients who died from respiratory failure was compared to the other patients. All patients who died from respiratory failure had fibrotic changes demonstrated by chest roentgenogram. All patients who died had at least one vital capacity less than 2.5 liters, with the majority of patients who died of respiratory failure having a vital capacity of less than 1.5 liters.
Patients who die from respiratory failure from their sarcoidosis have fibrosis demonstrated on chest roentgenogram and a reduced vital capacity, usually less than 1.5 liters.
尽管结节病是一种多系统疾病，但结节病导致的死亡通常归因于呼吸衰竭。为了识别那些有结节病呼吸衰竭死亡风险的患者，我们分析了在辛辛那提大学间质性肺病诊所就诊患者的七年经验。
在此期间共诊治了479例患者。其中，22例（4.6%）死亡。13例死于呼吸衰竭，3例死于心脏病，2例分别死于神经系统疾病或肝脏疾病。2例死于无关疾病。将死于呼吸衰竭的患者与其他患者进行分析比较。所有死于呼吸衰竭的患者胸部X线片均显示有纤维化改变。所有死亡患者的肺活量至少有一次低于2.5升，大多数死于呼吸衰竭的患者肺活量低于1.5升。
死于结节病呼吸衰竭的患者胸部X线片显示有纤维化且肺活量降低，通常低于1.5升。
